VANCOUVER, British Columbia, February 16, 2022 — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to report that Health Canada has added the Company’s wholly-owned subsidiary Optimi Labs Inc. to a list of approved suppliers under the Special Access Program (SAP). With a mission to provide compassionate, frontline solutions to Canada’s growing mental health crisis, the Company plans to supply psychedelics like psilocybin to those truly in need.
Announced on January 5, 2022, the SAP allows qualified medical practitioners to request access to Schedule 3 controlled substances such as psilocybin on a case-by-case emergency basis. Prior to the new regulatory amendments, medical practitioners were prohibited from requesting access to psilocybin and MDMA for individual psychedelic-assisted psychotherapy. The amendments have the potential to positively affect the lives of people experiencing serious mental health conditions and end-of-life distress when other therapies have failed, are unsuitable or are unavailable in Canada.
Optimi’s CEO, Bill Ciprick, says the SAP is already having a positive impact on patients in need and will provide the Company with the right avenue to develop and supply the demand for natural psilocybin.
“Between the science, research, and good manufacturing practices, the SAP is an excellent opportunity for all of us to learn, grow and expand our knowledge capacity and improve treatment outcomes for many people in the years to come,” added Ciprick.
With the Company’s Dealer’s License approved by Health Canada earlier this month, Optimi has received requests for supply agreements from potential partners interested in the Company’s new EU-GMP compliant 10,000 sq. ft. facility located in Princeton, British Columbia. Once fully commercialized, the production facility will position Optimi as a global frontrunner in the cultivation, extraction, and vertical integration of high-grade all-natural psilocybin.
“Establishing Optimi’s presence in the psychedelic market begins with trust, which we believe we have earned through our in-house expert research and world-class advisory team, and by setting the gold standard in GMP compliance,” added JJ Wilson, Optimi’s Chairman of the Board.
Optimi plans to host a grand opening of its new facility this May and is committed to building awareness and education about the benefits of the SAP to physicians qualified to recommend the program to patients.
ABOUT OPTIMI (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN)
Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional and psychedelic mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also been granted a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: https://optimihealth.ca/.